Shares of Inovio Pharmaceuticals INO jumped 20.6% on Wednesday after the FDA agreed to the company’s rolling submission timeline for the biologics license application (BLA) seeking approval for ...

Shares of Inovio Pharmaceuticals Inc. INO shed 8.85% to $2.37 Thursday, on what proved to be an all-around positive trading ...

Inovio Pharmaceuticals shares are currently trading just above a critical long-term technical indicator, suggesting potential stabilization after a period of volatility. The primary fundamental driver ...

Inovio Pharmaceuticals is a biotechnology company that designs and develops DNA medicines. Its business centers on discovering products that can treat cancers, infectious diseases, and rare disorders ...

Good afternoon, ladies and gentlemen, and welcome to the Inovio Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] This call is being recorded on Monday, November 10, 2025.

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...

Complete submission of the Biologics License Application (BLA) remains on track for 2H25 with the goal of file acceptance by U.S. Food and Drug Administration (FDA) by end of 2025 PLYMOUTH MEETING, Pa ...